Primary antibodies targeting CD markers
CD markers, and the antibodies directed against them, are widely used in human and animal models to study the immune system.
These markers play a crucial role in cancer research by enabling researchers to identify and track specific immune cell populations infiltrating within tumors.
Clusters of differentiation (CD) are surface molecules expressed on cells of the immune system such as lymphocytes (T-cells, B-cells, and NK-cells), neutrophils, and monocytes/ macrophages. CD molecules play key roles in immune cell-cell communication and sensing the microenvironment and are essential markers for the identification and isolation of the different cell types in the immune system.
Figure 1. Multiplexed immunofluorescence staining of human colorectal cancer tissue using primary antibodies against CD104 and CD324 to label the tumor cells, including monoclonals Anti-ITGB4 (CD104) (AMAb91454, red), and Anti-CDH1 (CD324) (AMAb90862, blue). In green is the polyclonal Anti-TJP1 (HPA001636).
Download Infographic - CD Markers
CD Markers in Cancer Research
In cancer research, CD markers are used to identify and isolate tumor cells from the surrounding normal tissue and to distinguish between different subtypes of cancer cells. They are also used to monitor treatment response and disease progression, as changes in the expression of certain CD markers can indicate tumor growth or regression.
CD44 is a cell surface glycoprotein that is overexpressed in breast cancer and is associated with cancer progression and metastasis.
CD166, also known as activated leukocyte cell adhesion molecule (ALCAM), is a cell surface protein that is overexpressed in prostate cancer cells and is associated with tumor progression and metastasis.